Eli Lilly’s retatrutide is under investigation in another six Phase III trials.

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Bimagrumab was shown to result in less total weight loss but better body composition. The fact that medication alone can cause fat loss and muscle gain at the same time was a "major breakthrough," ...

There are also other reasons to invest in Eli Lilly.

--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...

Novo Nordisk has multiple weight-loss drugs in various stages of development and approval, according to its R&D pipeline. These include, among others, monlunabant (phase 2); oral and subcutaneous ...